肿瘤细胞治疗研究
英文原题：CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting.
CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting.
这些数据支持MM治疗模式的转变，即更早地整合CAR-T疗法。
CAR-T 疗法正在迅速重塑多发性骨髓瘤（MM）的治疗格局。在 2025 ASH 年会上，关键性试验在复发/难治性和新诊断背景下均显示出显著疗效。在 KarMMa-3 中，一项针对老年患者（70 岁）的亚组分析显示，与标准治疗相比，idecabtagene vicleucel 显著改善了结局：总缓解率（ORR）81.6% vs. 48.1%，中位无进展生存期（PFS）18.9 vs. 5.7 个月，两组的中位总生存期（OS）均未达到。CARTITUDE-4 显示出更优的 30 个月 PFS（71.0% vs. 43.2%），而 iMMagine-1 报告 ORR 为 97%，微小残留病阴性率为 93%。值得注意的是，一线 CAR-T 研究取得了前所未有的结局，包括 100% ORR、接近 94-97% 的严格完全缓解率，以及 88-92% 的 30 个月 PFS 和 OS 率。总之，这些数据支持将 CAR-T 疗法更早整合到 MM 管理中的范式转变。
CAR-T therapy is rapidly reshaping the treatment paradigm of multiple myeloma (MM). At the 2025 ASH Annual Meeting, pivotal trials demonstrated marked efficacy across both relapsed/refractory and newly diagnosed settings. In KarMMa-3, a subgroup analysis of older patients ( 70 years) showed idecabtagene vicleucel significantly improved outcomes versus standard care: overall response rate (ORR) 81.6% vs. 48.1%, median progression-free survival (PFS) 18.9 vs. 5.7 months, with median overall survival (OS) not reached in either arm. CARTITUDE-4 showed superior 30-month PFS (71.0% vs. 43.2%), while iMMagine-1 reported an ORR of 97% with 93% minimal residual disease negativity. Notably, frontline CAR-T studies achieved unprecedented outcomes, including 100% ORR, stringent complete response rates approaching 94-97%, and 30-month PFS and OS rates of 88-92%. Together, these data support a paradigm shift toward earlier integration of CAR-T therapy in MM management.
MEMBER ACCOUNT
登录成功会直接打开下一页。
